The most significant advance in cancer treatment in decades is reaching fewer than 1 in 5 eligible patients.
We're here to change that.
CAR T-cell therapy is producing overall response rates of 60 to 80 percent in eligible patients with relapsed or refractory blood cancers, with roughly 30 to 40 percent achieving long-term remission, outcomes that were unimaginable a decade ago.
The barriers are not clinical. They are structural. Too few cancer programs have the capabilities, training, financial models, reimbursement strategies, and operational infrastructure to launch and sustain a cell therapy program. The result is a widening gap between what is possible for patients and what most oncology programs can actually deliver today.
acCELLapy exists to close the gap.
We partner with oncology providers, health systems, academic medical centers, and biopharma to build the capabilities required to safely launch, scale, and sustain CAR T-cell therapy programs so that more patients can access a treatment that may be their best, and in some cases only, curative option.
Why oncology programs need to act
CAR T-cell therapy has shifted from a niche capability at a limited number of centers to a strategic requirement for oncology programs. Indications are expanding, more patients are eligible, and organizations need a clear path to build safe, financially sound programs that bring advanced care closer to home.
The question is no longer whether cell therapy will become part of your cancer service line. The question is how quickly and safely your organization can build the capabilities to deliver it well.
Who we work with
We support organizations at different stages of cell therapy readiness, from first-time program launch to multi-site expansion and post-launch optimization.
What we do
We help clients answer the questions that determine whether a cell therapy program can launch, scale, and perform successfully.
- Strategy and business case
- Readiness and capability assessment
- Program design and implementation
- Clinical, quality, and compliance enablement
- Reimbursement and access support
- Post-launch support and expansion
Why acCELLapy is different
- We build with clients, not just advise them.
- We start at 80%, not zero.
- We connect strategy to bedside reality.
- We bring ecosystem partner optionality.
Many organizations begin with internal teams, shared documents, and strong intent. acCELLapy adds the specialized clinical, operational, and payor expertise needed to turn that foundation into a safe, scalable program.
See what sets us apartProof points
Our work is designed to accelerate readiness, reduce reinvention, and help clients build programs that are operationally sound, clinically grounded, and financially viable.
- Pre-developed tools, templates, and implementation assets
- Support across the full patient journey
- Integrated planning across clinical, quality, operational, and financial workstreams
- Ongoing support beyond launch
Build the right program from the start.
Whether you are evaluating a first launch, scaling an existing center, or extending access across a broader network, acCELLapy helps you move from strategy to implementation with confidence.
Start the conversation